40 related articles for article (PubMed ID: 11095582)
1. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of ethylene and ethylene oxide in subcellular fractions of lungs and livers of male B6C3F1 mice and male fischer 344 rats and of human livers.
Li Q; Csanády GA; Kessler W; Klein D; Pankratz H; Pütz C; Richter N; Filser JG
Toxicol Sci; 2011 Oct; 123(2):384-98. PubMed ID: 21785163
[TBL] [Abstract][Full Text] [Related]
3. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813
[TBL] [Abstract][Full Text] [Related]
4. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.
Khojasteh SC; Prabhu S; Kenny JR; Halladay JS; Lu AY
Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):1-16. PubMed ID: 21336516
[TBL] [Abstract][Full Text] [Related]
5. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
Helsby NA; Hui CY; Goldthorpe MA; Coller JK; Soh MC; Gow PJ; De Zoysa JZ; Tingle MD
Br J Clin Pharmacol; 2010 Dec; 70(6):844-53. PubMed ID: 21175440
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
Dogra M; Palmer BD; Bashiri G; Tingle MD; Shinde SS; Anderson RF; O'Toole R; Baker EN; Denny WA; Helsby NA
Br J Pharmacol; 2011 Jan; 162(1):226-36. PubMed ID: 20955364
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat.
Su QB; He F; Wang XD; Guan S; Xie ZY; Wang LY; Lu YJ; Gu LQ; Huang ZS; Chen X; Huang M; Zhou SF
Invest New Drugs; 2008 Apr; 26(2):119-37. PubMed ID: 17922078
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.
Brandon EF; Sparidans RW; van Ooijen RD; Meijerman I; Lazaro LL; Manzanares I; Beijnen JH; Schellens JH
Invest New Drugs; 2007 Feb; 25(1):9-19. PubMed ID: 16633717
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.
Brandon EF; Sparidans RW; Guijt KJ; Löwenthal S; Meijerman I; Beijnen JH; Schellens JH
Invest New Drugs; 2006 Jan; 24(1):3-14. PubMed ID: 16379042
[TBL] [Abstract][Full Text] [Related]
10. Transport of thalidomide by the human intestinal caco-2 monolayers.
Zhou S; Li Y; Kestell P; Schafer P; Chan E; Paxton JW
Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):49-61. PubMed ID: 16010862
[TBL] [Abstract][Full Text] [Related]
11. 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3.
Zhou S; Kestell P; Paxton JW
Eur J Drug Metab Pharmacokinet; 2002; 27(3):179-83. PubMed ID: 12365199
[TBL] [Abstract][Full Text] [Related]
12. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
[TBL] [Abstract][Full Text] [Related]
13. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
15. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.
Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR
Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200
[TBL] [Abstract][Full Text] [Related]
16. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
17. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
18. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Zhou S; Kestell P; Paxton JW
Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
